关键词
How to Cite
摘要
Расширение арсенала лекарственных препаратов для лечения метастатического рака молочной железы (мРМЖ) определяет необходимость оптимизации существующих подходов к выстраиванию наиболее эффективной линейности терапии. С появлением в клинической практике новых коньюгатов моноклональных антител, нацеленных на определенный рецептор, совмещенных с цитостатиком, поставило этот вопрос в отношении терапии пациентов тройным негативным (ТН) и HER2-low РМЖ. В статье представлен обзор основных исследований эффективности сацитузумаба говитекана и трастузумаба дерукстекана в контексте последней версии клинических рекомендаций по лечению данных вариантов метастатического рака молочной железы. Накопление практического опыта и обобщение его в исследованиях реальной клинической практики позволят клиническим онкологам окончательно сформировать стратегию последовательного применения вновь появляющихся конъюгатов.
参考
Ассоциация онкологов России, Общероссийская общественная организация «Российское общество клинической онкологии», Общероссийская общественная организация «Российское общество онкомаммологов». Клинические рекомендации: «Рак молочной железы». Ассоциация Онкологов России. 2021; 63-75. URL: https://oncology-association.ru/wp-content/uploads/2021/02/rak-molochnoj-zhelezy-2021.pdf?ysclid=lvs0u0equo888706340 [Association of Oncologists of Russia, All-Russian public organization «Russian Society of Clinical Oncology», All-Russian public organization «Russian Society of Oncomammologists». Clinical guidelines: Breast Cancer. Association of Oncologists of Russia. 2021; 63-75. URL: https://oncology-association.ru/wp-content/uploads/2021/02/rak-molochnoj-zhelezy-2021.pdf?ysclid=lvs0u0equo888706340 (In Rus)].
Cardillo T., Govindan S., Sharkey R., et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015; 26(5): 919-31.-DOI: https://doi.org/10.1021/acs.bioconjchem.5b00223.
Bardia A., Hurvitz S.A., Tolaney S.M., et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021; 384: 1529-154.-DOI: https://doi.org/10.1056/NEJMoa2028485.
Identification and Disclosure of Relationships with External Entities. National Comprehensive Cancer Network. URL: https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panels.
Daiichi Sankyo. Datopotamab deruxtecan continues to show promising durable response and disease control in patients with metastatic triple negative breast cancer. Press Release, oral presentation (GS1-05) at the 2021 San Antonio Breast Cancer Symposium (#SABCS21). Tokyo. Munich and Basking Ridge, NJ. 2021; 5. URL: https://daiichisankyo.us/documents/364091/11622249/Dato-DXd+TNBC+SABCS+Data+Release+FINAL.pdf/d9080e7c-957d-45b4-5370-6d5972b5cb80.
Wolff A.C., McShane L.M., Hammond M.E.H., et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update. Arch Pathol Lab Med. 2018; 142(11): 1364-2. URL: https://meridian.allenpress.com/aplm/article/142/11/1364/103146/Human-Epidermal-Growth-Factor-Receptor-2-Testing (23.04.2023).
Von Minckwitz G., du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol. 2009; 27(12): 1999-2006.-DOI: https://doi.org/10.1200/JCO.2008.19.6618.
Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28(7): 1124-1130.-DOI: https://doi.org/10.1200/JCO.2008.21.4437.
Burris H.A. 3rd, Rugo H.S., Vukelja S.J., et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011; 29(4): 398-405.-DOI: https://doi.org/10.1200/JCO.2010.29.5865.
Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19): 1783-1791-DOI: https://doi.org/10.1056/NEJMoa1209124.
Nakada T., Sugihara K., Jikoh T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019; 67: 173-85.-DOI: https://doi.org/10.1248/cpb.c18-00744.
Modi S., Saura C., Yamashita T., et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020; 382(7): 610-621.-DOI: https://doi.org/10.1056/NEJMoa1914510.
Chung W.P., Kim S.B., Chung W.-P., et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022; 386(12): 1143-1154.-DOI: https://doi.org/10.1056/NEJMoa2115022.
Modi S., Jacot W., Yamashita T., et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022; 387(1): 9-20.-DOI: https://doi.org/10.1056/NEJMoa2203690.
Hein A., Hartkopf A., Emons J., et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021; 155: 1-12.-DOI: https://doi.org/10.1016/j.ejca.2021.06.033.
Denkert C., Seither F., Schneeweiss A., et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021; 22: 1151-61.-DOI: https://doi.org/10.1016/S1470-2045(21)00301-6).
Fehrenbacher L., Cecchini R.S., Geyer C.E., et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020; 38(5): 444-453.-DOI: https://doi.org/10.1200/JCO.19.01455.
Enhertu. Summary of product characteristics. Pfaffenhofen, Germany: Daiichi Sankyo Europe GmbH. 2023: 47. URL: https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf.
Robson M., Im S.A., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017; 377(6): 523-533.-DOI: https://doi.org/10.1056/NEJMoa1706450.
Senkus E., Delaloge S., Domchek S.M., et al. Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer. 2023; 153(4): 803-814.-DOI: https://doi.org/10.1002/ijc.34525.
Litton J.K., Rugo H.S., Etti J., et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018; 379(8): 753-63.-DOI: https://doi.org/10.1056/NEJMoa1802905.
Fitzgibbons P.L., Dillon D., Alsabeh R., et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2014; 138(5): 595-601.-DOI: https://doi.org/10.5858/arpa.2013-0566-CP.
Tarantino P., Hamilton E., Tolaney S.M., et al. HER2-Low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020; 38(17): 1951-62. URL: https://pubmed.ncbi.nlm.nih.gov/32330069/ (23.04.2023).
Tarantino P., Viale G., Press M.F., et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol. 2023; 34(8): 645-659.-DOI: https://doi.org/10.1016/j.annonc.2023.05.008.
Апанасевич В.И., Артамонова Е.В., Ашрафян Л.А., и др. Клинические рекомендации Российского общества онкомаммологов «Золотой стандарт профилактики, диагностики, лечения и реабилитации больных РМЖ». Сайт Российского общества онкомаммологов РООМ. 2024; 297. URL: https://docs.google.com/document/d/14XU19rSHmmg0v8aL9msY9B1uoscVK7WS/edit?tab=t.0#heading=h.gjdgxs (25.05.2023).
[Apanasevich V.I., Artamonova E.V., Ashrafyan L.A., et al. Clinical recommendations of the Russian Society of Oncology and Mammology “Gold standard for prevention, diagnosis, treatment and rehabilitation of patients with breast cancer”. Website of the Russian Society of Oncomammologists RSOM. 2024; 297. URL: https://docs.google.com/document/d/14XU19rSHmmg0v8aL9msY9B1uoscVK7WS/edit?tab=t.0#heading=h.gjdgxs (25.05.2023). (In Rus)].
Zhang H., Peng Y. Current biological, pathological and clinical landscape of HER2-low breast cancer. Cancers (Basel). 2022; 15(1): 126.-DOI: https://doi.org/10.3390/cancers15010126.
ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000. Trial ID: NCT04494425. A phase 3, randomized, multi-center, open-label study of trastuzumab deruxtecan (T-DXd) versus investigator's choice chemotherapy in HER2-low, hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting (DESTINY-Breast06). 2021-01-21. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-004493-26/IT.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2024